Standard treatment for liver metastases with gastrointestinal stromal tumors

Lin CHEN,Li-cheng LIU
DOI: https://doi.org/10.7504/CJPS.ISSN1005-2208.2015.04.15
2015-01-01
Abstract:Gastrointestinal stromal tumor (GIST) with liver metastases could occur at each risk grade/pathological staging, and seriously affect the survival rate of patients. The rate of liver metastasis from GIST is 15.9%. The treatment for GIST has been an urgent problem in the surgical field. Surgical procedures were important to the patients with GIST. Patients with GIST performed complete tumor resection and taking imatinib postoperatively could have good prognosis. The choice of the surgery ways depends more on the location andsize of tumors. Surgical therapy combined with tyrosine kinase inhibitors (TKI) may be an effective method, and increase the overall survival and improve the quality of survival for patients with liver metastasis significantly. TKI combined surgical treatment is the optimal strategy for GIST with liver metastasis.
What problem does this paper attempt to address?